30
November 2016
Global First IND for Subcutaneous Injectable anti-PD-L1 Domain Antibody Receives FDA Approval
SUZHOU, China & CHENGDU, China--(BUSINESS WIRE)-3D Medicines (Sichuan) Co., Ltd. and Suzhou Alphamab Co., Ltd. announced today that the U.S. FDA has completed its review of the IND for their drug KN03...
